Establishment of New Business Venture by Takeda Pharmaceutical Company Ltd. and Teva Pharmaceutical Industries Ltd.

Mr. Ota has a wealth of practical international and domestic legal experience, focusing on the areas of hostile takeovers, shareholder activism, M&A transactions (including cross-border deals), corporate governance and other corporate matters, domestic/international taxation, and personal information/data protection, and works on a wide range of corporate legal affairs cases. In the NIKKEI’s "Most Successful Lawyers" awards he was ranked in the corporate law category (1st) and the tax category (2nd) in 2024; in the corporate law category (1st) and the M&A category (1st) in 2023; and in the corporate law category (1st) in 2022. In addition, he dedicates himself to research and writing activities that bridge academia and legal practice on cutting-edge issues related to the Companies Act, the Financial Instruments and Exchange Act, tax law, the Act on the Protection of Personal Information, etc. He has edited and authored many books and papers, such as "Introduction to Corporate Governance" (Iwanami Shinsho), "Hostile Takeovers and Activists" (Iwanami Shinsho), “Schemes and Tax Issues of M&A and Corporate Restructuring, 4th Ed.”, “Corpus Juris M&A - Completely Revised Edition (first volume) (second volume)”, “Handbook on Share Options (Fifth Edition)”, “Corpus Juris Series - Personal Information Protection Legislation (Global)”, “Handbook on Class Shares”, etc.

Hiroko Shibata has extensive experience advising a broad range of Japanese and international clients on domestic and cross-border M&A transactions. She has excels at handling M&A transactions involving multiple jurisdictions, and those requiring complex, detailed structuring and implementation. She also handles numerous matters involving corporate governance, as well as employment issues, and has in-depth knowledge and expertise in the areas of executive compensation, employment benefit plans, and related laws and regulations, including taxation.